Logo
Company Profile

Newronika SPA

EIC Accelerator Program Supports Newronika's Deep Brain Stimulation Technology Development and Capital Growth

ItalyEIC Accelerator2022

Table of Contents

  1. The EIC Accelerator Project
  2. The Funding Rounds
  3. The Press Releases
  4. The Technology Advancements
  5. The Partnerships and Customers
  6. The Hiring and Company Growth
  7. The Media Features and Publications

1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator is a flagship funding program under the European Innovation Council (EIC), designed to support innovative startups and small-to-medium enterprises (SMEs) in Europe. Launched as part of the EU's Horizon Europe program, the EIC Accelerator aims to foster the development of breakthrough technologies and disruptive innovations, particularly in the DeepTech sector.

Key Features of the EIC Accelerator:

1. Funding Structure:
  • Grants: Up to €2.5 million can be awarded to support project development, prototyping, market entry, and scaling.
  • Equity Investment: The program also provides equity funding, with up to €15 million available until 2024, decreasing to €10 million from 2025 onward. This equity investment can help startups secure further funding and scale effectively.
2. Phased Application Process:
  • The application process is divided into three steps:
  • Step 1: Expression of interest and initial proposal submission.
  • Step 2: In-depth proposal submission focusing on the project's feasibility and impact.
  • Step 3: An interview with a panel of experts to assess the project's viability, scalability, and potential market impact.
3. Target Audience:
  • Primarily aimed at high-risk, high-reward innovations, the EIC Accelerator is designed to support companies that have a strong potential for growth and societal impact.

    • Purpose of the EIC Accelerator

    The EIC Accelerator plays a crucial role in the European DeepTech and startup ecosystem by:

    • Promoting Innovation: It encourages the development of cutting-edge technologies and solutions that can address significant societal challenges, such as healthcare, sustainable energy, and digital transformation.
    • Fostering Entrepreneurship: By providing financial support, it helps entrepreneurs turn innovative ideas into viable businesses.
    • Creating Jobs and Economic Growth: The program aims to stimulate job creation and economic growth by enabling startups to scale and succeed in competitive markets.

    Role in Scaling and Funding

    The EIC Accelerator is instrumental in helping companies scale through:

    • Access to Capital: The combination of grants and equity investments allows companies to secure necessary funding, reducing reliance on traditional financing methods.
    • Private Sector Engagement: By demonstrating commitment through initial funding, the EIC Accelerator encourages private investors to come on board, thereby increasing the overall investment into the company.
    • Networking and Mentorship: Winners of the EIC Accelerator often gain access to a network of experts, mentors, and potential collaborators, which can further enhance their growth trajectory.

    EIC Accelerator Winner: Newronika SPA

    Company Overview

    • Name: Newronika SPA
    • Website: newronika.com
    • Country: Italy
    • Project Acronym: alphadbs
    • Project Description: Adaptive Deep Brain Stimulation (DBS)
    • Funding Type: Grant first
    • Submission Date: October 5, 2022

    Project Summary: alphadbs

    Newronika SPA's project, alphadbs, focuses on developing an Adaptive Deep Brain Stimulation (DBS) system. This innovative technology aims to address neurological disorders by delivering targeted electrical impulses to specific brain regions, thereby alleviating symptoms associated with conditions such as Parkinson's disease, epilepsy, and depression.

    Technology Basics and Background

    Deep Brain Stimulation (DBS) is a neurosurgical procedure that involves implanting a device that sends electrical impulses to specific brain areas. The technology has gained traction in the treatment of various neurological disorders, with a significant focus on:

    1. Mechanism: DBS involves the implantation of electrodes in the brain, which are connected to a pulse generator. This generator can be programmed to deliver electrical stimulation to modulate abnormal brain activity.
    2. Adaptive Technology: Unlike traditional DBS systems, which deliver constant stimulation, the alphadbs system is designed to adapt in real-time based on the patient's neural activity. This personalization enhances effectiveness and minimizes side effects.
    3. Clinical Applications: The potential applications of alphadbs extend beyond Parkinson’s disease to include other movement disorders, chronic pain management, and psychiatric conditions.
    4. Research and Development: The project involves extensive research into neural patterns, algorithms for adaptive stimulation, and clinical trials to ensure efficacy and safety.

    By leveraging the EIC Accelerator’s funding, Newronika SPA can further develop its innovative DBS technology, paving the way for more effective treatments for individuals suffering from debilitating neurological disorders, ultimately improving their quality of life.

    2 The Funding Rounds

    Since receiving the EIC Accelerator funding on October 5, 2022, Newronika S.p.A., an Italian company specializing in deep brain stimulation (DBS) technologies, has secured additional funding to advance its innovative treatments for Parkinson's disease.

    Funding Rounds:

  • February 13, 2025: Newronika closed a €13.6 million Series B financing round. This funding was led by Fondazione ENEA Tech Biomedical, with participation from existing investors Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. The capital is intended to expand the clinical validation and commercialization of Newronika's proprietary adaptive DBS system. (finsmes.com)

    • Investor Information:

    • Fondazione ENEA Tech Biomedical: A new investor leading the Series B round.
    • Indaco Venture Partners SGR: An existing investor participating in the Series B round.
    • Innogest SGR: An existing investor participating in the Series B round.
    • Wille Finance: An existing investor participating in the Series B round.
    • TNBT Capital: An existing investor participating in the Series B round.
    • F3F: An existing investor participating in the Series B round.

    Company Valuations:

    As of the latest available data, Newronika's valuation is not publicly disclosed. The company has raised a total of approximately $59.3 million across various funding rounds, including the €13.6 million Series B round in February 2025. (pitchbook.com)

    Additional Information:

    Newronika's adaptive DBS system aims to provide personalized therapy for Parkinson's disease patients by continuously optimizing stimulation based on real-time neural data. The recent funding will support the advancement of product pipelines, talent recruitment, and strategic collaborations to strengthen the company's position in the medical device and neuroscience sectors. (finsmes.com)

    Prior to the Series B round, Newronika secured a €8.4 million Series A funding round in September 2019, led by Omnes Capital, with participation from Innogest Capital and Indaco Venture Partners SGR. (innogestcapital.com)

    In summary, since receiving the EIC Accelerator funding in October 2022, Newronika has successfully raised €13.6 million in Series B funding to further develop and commercialize its adaptive DBS technology.

    3 The Press Releases

    Since receiving the EIC Accelerator funding on October 5, 2022, Newronika S.p.A. has made significant strides in advancing its adaptive deep brain stimulation (DBS) technology. Notable developments include:

    1. Receipt of EIC Accelerator Grant: On January 22, 2024, Newronika secured a €2.5 million grant from the European Innovation Council (EIC) Accelerator. This funding is designated to support a pivotal European clinical trial of their adaptive DBS system, aiming to enhance treatment outcomes for Parkinson's disease patients. (newronika.com)

    2. Leadership Appointment: On September 21, 2022, Lothar Krinke was appointed as the CEO of Newronika, marking a new phase in the company's development of adaptive neuromodulation products. (newronika.com)

    3. Series B Financing: On February 13, 2025, Newronika announced the successful closure of a €13.6 million Series B funding round. The financing was led by Fondazione ENEA Tech e Biomedical, with participation from existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. This capital is intended to accelerate the clinical validation and commercialization of Newronika's proprietary adaptive DBS system, designed to deliver precision therapy for Parkinson's disease patients. (wate.com)

    4. FDA Investigational Device Exemption (IDE): On February 5, 2025, Newronika received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). This approval allows the company to initiate a pivotal U.S. clinical trial to evaluate the safety and efficacy of its adaptive DBS system for patients with movement disorders, including Parkinson's disease. (fox5sandiego.com)

    5. CE Mark for AlphaDBS System: In February 2021, Newronika's AlphaDBS system, a closed-loop brain neuromodulation implant, received the CE Mark, indicating compliance with European Union health, safety, and environmental protection standards. (owler.com)

    These developments underscore Newronika's commitment to advancing neuromodulation therapies and improving the quality of life for individuals with Parkinson's disease.

    4 The Technology Advancements

    Since receiving the European Innovation Council (EIC) Accelerator funding on October 5, 2022, Newronika S.p.A., an Italian company specializing in adaptive deep brain stimulation (DBS) technologies, has achieved several significant advancements:

    Technological Improvements and New Features:

    • FDA Investigational Device Exemption (IDE): On February 5, 2025, Newronika announced that the U.S. Food and Drug Administration granted an IDE for its adaptive DBS system. This approval allows the company to initiate a clinical trial in the U.S., focusing on patients with movement disorders such as Parkinson's disease. The adaptive DBS system utilizes real-time feedback from patients' brain signals to deliver personalized brain stimulation therapy, marking a significant advancement over traditional DBS methods. (third-news.com)
    • Series B Financing: On February 13, 2025, Newronika successfully closed a €13.6 million Series B funding round. This financing, led by Fondazione ENEA Tech e Biomedical and supported by existing investors, aims to accelerate the development and commercialization of their adaptive DBS platform. The funds are intended to expand clinical validation, advance product pipelines, and establish strategic collaborations, reinforcing Newronika's position in the neuromodulation field. (wcia.com)

    Market Demonstrations and Clinical Trials:

  • Clinical Trials: Newronika has been actively involved in clinical trials to validate the safety and efficacy of its adaptive DBS system. Notably, a double-blind crossover study (NCT04681534) is recruiting participants to evaluate the system in patients with Parkinson's disease. This study aims to compare the outcomes of adaptive DBS against conventional methods, providing valuable insights into the system's effectiveness. (synapse.patsnap.com)

    • Patents and Scientific Publications:

    • Patents: As of November 1, 2024, Newronika has filed patents related to its adaptive DBS technology. These patents are crucial for protecting the company's innovations and ensuring a competitive edge in the market. (synapse.patsnap.com)
    • Scientific Publications: Newronika has been featured in scientific literature discussing innovations in neurostimulation. For instance, an article in IEEE Pulse highlights the company's development of an adaptive DBS system that adjusts stimulation based on real-time brain activity, offering a more personalized approach to treating Parkinson's disease. (embs.org)

    These developments underscore Newronika's commitment to advancing neuromodulation therapies and improving patient outcomes through innovative technologies.

    5 The Partnerships and Customers

    Since receiving the EIC Accelerator funding on October 5, 2022, Newronika S.p.A., an Italian company specializing in adaptive deep brain stimulation (DBS) technologies, has secured significant partnerships and customers that bolster its market position and technological advancements.

    New Partners:

  • Fondazione ENEA Tech e Biomedical: In February 2025, Newronika closed a €13.6 million Series B financing round, led by Fondazione ENEA Tech e Biomedical, with participation from existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. (wcia.com)

    • Nature and Purpose of the Relationship:

    • Strategic Investment: Fondazione ENEA Tech e Biomedical's investment aims to accelerate the development and commercialization of Newronika's proprietary adaptive DBS system, enhancing precision therapy for Parkinson's disease patients. (wcia.com)
    • Support for Clinical Validation: The funding is designated for expanding clinical validation and advancing product pipelines, facilitating the recruitment of top-tier talent, and establishing strategic collaborations to strengthen Newronika's position at the intersection of medical device engineering and neuroscience. (wcia.com)

    Impact on Market Position:

    • Enhanced Market Presence: The substantial investment and strategic partnership with Fondazione ENEA Tech e Biomedical position Newronika as a leader in the adaptive DBS market, enabling the company to offer advanced, personalized therapies for neurological disorders. (wcia.com)
    • Competitive Edge: The collaboration provides Newronika with the resources to scale operations, improve product offerings, and expand its reach in the global healthcare market.

    Advancements in Technology and Scaling:

    • Accelerated Product Development: The funding supports the clinical validation and commercialization of Newronika's adaptive DBS system, facilitating the integration of real-time neural data and machine learning into DBS devices for personalized therapies. (wcia.com)
    • Expansion of Capabilities: The partnership enables Newronika to recruit top-tier talent and establish strategic collaborations, enhancing its technological capabilities and scaling efforts in the neuromodulation sector. (wcia.com)

    These developments underscore Newronika's commitment to advancing neuromodulation technologies and improving patient outcomes through innovative partnerships and strategic investments.

    6 The Hiring and Company Growth

    Newronika S.p.A., an Italian company specializing in advanced deep brain stimulation (DBS) technologies, has demonstrated significant growth and strategic development since receiving €2.5 million in grant funding from the European Innovation Council (EIC) Accelerator on October 5, 2022. (ec.europa.eu)

    Current Team Size and Hiring Status:

    Specific details regarding Newronika's current headcount and team size are not publicly disclosed. However, the company has been actively expanding its team to support its growth initiatives. In February 2025, Newronika successfully closed a €13.6 million Series B financing round, led by Fondazione ENEA Tech e Biomedical, with participation from existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. (wcia.com) This substantial funding is expected to bolster the company's hiring efforts, particularly in areas critical to scaling operations and advancing product development.

    Growth and Recent Hires:

    While specific information about recent key hires is not publicly available, the Series B funding is earmarked for several strategic initiatives:

    • Clinical Validation and Commercialization: Accelerating the development and market introduction of Newronika's proprietary adaptive DBS system, Alpha-DBS, which aims to provide personalized therapy for Parkinson's disease patients.
    • Product Pipeline Advancement: Expanding the range of products and solutions offered by the company to address a broader spectrum of neurological disorders.
    • Talent Acquisition: Recruiting top-tier professionals to strengthen the company's capabilities in medical device engineering and neuroscience.

    The influx of capital and the focus on talent acquisition are poised to enhance Newronika's ability to innovate and scale its operations effectively. By integrating real-time neural data and machine learning into its DBS systems, the company aims to deliver personalized therapies that surpass existing market offerings, thereby improving patient outcomes and solidifying its position in the neuromodulation sector.

    Management and Founding Team Changes:

    As of the latest available information, there have been no publicly reported major changes in Newronika's management or founding team. The company's leadership continues to be guided by Dr. Lorenzo Rossi, Co-Founder and CEO, who has been instrumental in steering the company's strategic direction and securing significant funding to support its growth initiatives. (wcia.com)

    In summary, since receiving the EIC Accelerator funding in October 2022, Newronika has demonstrated substantial growth through strategic funding rounds and a clear focus on expanding its team and product offerings. These efforts are expected to drive the company's mission of revolutionizing deep brain stimulation therapies and improving the quality of life for patients with neurological disorders.

    7 The Media Features and Publications

    Since receiving the EIC Accelerator funding on October 5, 2022, Newronika S.p.A. has been featured in several media outlets, participated in industry events, and secured significant funding to advance its deep brain stimulation (DBS) technology. Below is a summary of these activities:

    Media Features:

    • February 13, 2025: Newronika announced the successful closing of a €13.6 million Series B funding round, led by Fondazione ENEA Tech e Biomedical, with participation from existing investors such as Indaco Venture Partners SGR, Innogest SGR, Wille Finance, TNBT Capital, and F3F. This funding aims to accelerate the development of their adaptive DBS platform. (wate.com)
    • February 13, 2025: The funding round was also covered by BioSpace, highlighting Newronika's commitment to transforming deep brain stimulation by integrating real-time neural data and machine learning into their DBS systems. (biospace.com)
    • February 13, 2025: MassDevice reported on Newronika's €13.6 million Series B funding, emphasizing the company's plans to expand clinical validation and commercialization of its proprietary adaptive DBS system. (massdevice.com)

    Publications Mentioning Newronika S.p.A.:

  • February 13, 2025: Investors Hangout featured an article detailing Newronika's €13.6 million Series B funding round, discussing the investors involved and the company's strategic vision for advancing DBS technology. (investorshangout.com)

    • Podcasts or Interviews:

  • 2021: An interview with Dr. Lorenzo Rossi, CEO of Newronika, was featured in the "Italy Life Sciences 2021" report, discussing the company's innovative approach to DBS and its future development plans. (projects.gbreports.com)

    • Conference and Fair Participation:

  • November 2021: While specific details about Newronika's participation in industry fairs during this period are not available, the company has been active in presenting its technologies at various industry events.

    • Event Involvement:

  • February 2025: Newronika's participation in the €13.6 million Series B funding round indicates active engagement with investors and stakeholders in the medical technology sector.

    • These activities underscore Newronika's ongoing efforts to advance its DBS technology and expand its presence in the medical device industry.

    EIC Accelerator Winner - 2022